Matica Biolabs is a specialised contract development and manufacturing organisation (CDMO) dedicated to the development and production of advanced cell and gene therapies. The company operates within the CHA Biotech group and focuses on delivering manufacturing solutions that help its clients advance complex biologics from process development through clinical production. Its services adhere to global standards and are supported by experienced technical teams that aim to streamline manufacturing processes and support customers in bringing therapies to market.

Key Products and Services

• Contract development and manufacturing for cell and gene therapy products.
• Advanced biologics manufacturing aligned with global regulatory requirements.
• Production process development for clinical and commercial supply.
• End-to-end support, from early-stage process design to GMP-compliant manufacturing.
• Facilities equipped to manage diverse cellular modalities and advanced biopharmaceutical workflows.

Matica Biolabs has established a manufacturing base in Korea to support both local and international clients developing cell and gene therapies. It holds multiple regulatory permits required for advanced biologics production, including licences for manufacturing and processing a broad range of cellular materials. These credentials position the company as a partner capable of supporting complex therapeutic programmes from development through clinical manufacture, underpinned by systematic process management and adherence to current good manufacturing practice.